| pubmed-article:1649715 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0030281 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0017631 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0017725 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:1649715 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:1649715 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1649715 | pubmed:dateCreated | 1991-8-23 | lld:pubmed |
| pubmed-article:1649715 | pubmed:abstractText | 1. Sulphonylurea derivatives are commonly used in the treatment of non-insulin-dependent diabetes mellitus. It is, however, unclear whether the hypoglycaemic effect of sulphonylurea derivatives is additive to the effect of glucose, or whether sulphonylurea derivatives act by increasing B-cell glucose sensitivity. 2. We assessed the effect of gliclazide on glucose-stimulated insulin secretion in eight healthy volunteers. Sixty minute hyperglycaemic glucose clamps (blood glucose levels of 8, 11 and 32 mmol/l) were performed, with and without prior administration of gliclazide (80 mg) 90 min before the glucose clamp. 3. Dose-response characteristics were assessed with a modified Michaelis-Menten equation. The Vmax. (maximal B-cell responsiveness) was not significantly changed (1.5 +/- 0.1 versus 1.3 +/- 0.2 and 5.0 +/- 0.5 versus 4.8 +/- 0.5 mmol/l for the first- and second-phase insulin secretion, respectively), whereas the ED50 (half-maximally stimulating blood glucose concentration) was significantly decreased by gliclazide for first-phase insulin secretion (7.6 +/- 0.3 versus 9.1 +/- 0.6 mmol/l) but not for second-phase insulin secretion (12.0 +/- 0.5 versus 12.3 +/- 0.5 mmol/l). 4. We conclude that gliclazide indeed leads to a shift to the left of the dose-response curve of first-phase insulin release in vivo without a change in Vmax, which indicates an apparent enhancement of B-cell glucose sensitivity. | lld:pubmed |
| pubmed-article:1649715 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1649715 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1649715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1649715 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1649715 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1649715 | pubmed:issn | 0143-5221 | lld:pubmed |
| pubmed-article:1649715 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:1649715 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:1649715 | pubmed:author | pubmed-author:VenemanT FTF | lld:pubmed |
| pubmed-article:1649715 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1649715 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:1649715 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1649715 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1649715 | pubmed:pagination | 101-6 | lld:pubmed |
| pubmed-article:1649715 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:meshHeading | pubmed-meshheading:1649715-... | lld:pubmed |
| pubmed-article:1649715 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1649715 | pubmed:articleTitle | Effect of acute administration of gliclazide on the glucose sensitivity of pancreatic B-cells in healthy subjects. | lld:pubmed |
| pubmed-article:1649715 | pubmed:affiliation | Department of Endocrinology, Free University Hospital, Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:1649715 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1649715 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1649715 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1649715 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:1649715 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
